<< SXC Health Solutions declares nominal dividend on common shares | Sigma-Aldrich Corporation announces global release of engineered mammalian cell lines >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | Nederlands | עִבְרִית | Русский | Polski

Dietary supplement combining zinc, phytase enhances effectiveness of BTX injections: Study

Published on September 2, 2010 at 7:52 AM · No Comments

Taking a dietary supplement of organic zinc and the enzyme phytase four days before receiving botulinum toxin injections made the toxin more effective in 93 percent of patients tested in a recent study at The Methodist Hospital in Houston.

Dr. Charles Soparkar's research has resulted in a patent-pending dietary supplement combining zinc and phytase (trademarked as ZYTAZE™) to be available to patients as early as this month. Forty-one of the 44 patients who took the oral supplements prior to botulinum toxin injections (Botox®, Dysport®, or Myobloc®) showed improved results. Many of the patients in the study were being treated for a rare form of eyelid spasm called blepharospasm and had previously responded poorly to botulinum toxin injections.

Soparkar's research team will present the effect of dietary zinc supplementation on botulinum toxin treatments at the American Society of Ophthalmic Plastic & Reconstructive Surgery's 41st Annual Fall Scientific Symposium on Oct. 14 in Chicago.

"Surprisingly, the results showed that in over ninety percent of the patients studied, the zinc/phytase combination resulted in a remarkable improved responsiveness to treatment of blepharospasm using the same amount of botulinum toxin as previously used," said Soparkar, M.D., Ph.D., an oculoplastic surgeon at The Methodist Hospital. "The toxins seemed to have greater effect and last longer. Potentially, this could mean using less toxin, offering patients financial savings, greater safety, and more consistent results."

Physicians began using botulinum toxin for blepharospasm in the 1980s. Today, Botox®, the first FDA approved botulinum toxin, is commonly used for cosmetic purposes as well as the treatment of many medical conditions.

ZYTAZE is licensed to OCuSOFT, Inc., a company dedicated to ophthalmic research, development and patient care, and will be available as a prescription supplement.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading